{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-271925","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.015275+00:00","generated_at":"2026-06-08T18:19:37.525633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"XOMA reports Q3 net loss of $5.5M, highlights NDA filings and $5M milestone from Day One","bullets":["Q3 revenues $0.8M vs $0.5M YoY; net loss $5.5M vs $4.2M YoY.","G&A expenses $6.4M including $2.7M non-cash stock comp; net cash used in ops $2.1M.","Received $6.6M in royalty & milestone payments; ended Q3 with $33.5M cash.","Subsequent: earned $5M milestone from Day One on FDA acceptance of tovorafenib NDA; PDUFA April 30, 2024.","Organon terminated license for ebopiprant; XOMA to seek out-licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-271925","json":"https://secwatch.observer/filing/0001193125-23-271925.json","markdown":"https://secwatch.observer/filing/0001193125-23-271925.md","text":"https://secwatch.observer/filing/0001193125-23-271925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523271925/0001193125-23-271925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523271925/d893832d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:19:37.525633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f002b6bcc4801990cb31fe3b293b9a9d42b3bd94","claim":"XOMA Royalty Corp reported financial results for the third quarter of 2023.","evidence_excerpt":"On November 7, 2023, XOMA Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312523271925/0001193125-23-271925-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}